# Pierre Fabre

Source: https://onco.cc/companies/pierre-fabre/  
OnCo record `pierre-fabre` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pierre Fabre is a French pharmaceutical and dermo-cosmetics group whose oncology franchise includes vinorelbine (Navelbine), vinflunine (Javlor) and the BRAF/MEK pair encorafenib and binimetinib in Europe.

## Summary

Pierre Fabre, based in Castres, is a French pharmaceutical and dermo-cosmetics group whose oncology franchise includes vinorelbine, sold as Navelbine, vinflunine, sold as Javlor, and the BRAF and MEK pair encorafenib and binimetinib in Europe. It originated the vinca alkaloids vinorelbine and vinflunine, markets Braftovi and Mektovi in Europe under licence from Array and Pfizer, and sells busulfan as Busilvex and other haematology products. OnCo links it to the vinflunine drug record. Whether a mid-sized European company can keep a targeted therapy franchise built on in-licensed products as their originators change hands is the open question. Vinflunine has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Castres
- Type: pharma
- Website: https://www.pierre-fabre.com

## Sources

- Official website: https://www.pierre-fabre.com

## Connected records

- targets: [BRAF](https://onco.cc/targets/braf/), [MEK1/2](https://onco.cc/targets/mek/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Busulfan](https://onco.cc/drugs/busulfan/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Propranolol (Hemangeol)](https://onco.cc/drugs/propranolol-hemangeol/), [Tabelecleucel](https://onco.cc/drugs/tabelecleucel/), [Vinflunine](https://onco.cc/drugs/vinflunine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu](https://onco.cc/trials/nct03394365/), [A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases](https://onco.cc/trials/nct04554914/), [Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.](https://onco.cc/trials/nct05270044/), [Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen](https://onco.cc/trials/nct06640166/), [Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer](https://onco.cc/trials/nct05706779/), [FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations](https://onco.cc/trials/nct06669117/), [First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations](https://onco.cc/trials/nct06043817/), [Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung](https://onco.cc/trials/nct05195632/), [Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs](https://onco.cc/trials/nct06567015/), [Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial](https://onco.cc/trials/nct06207656/)

---
JSON: https://onco.cc/api/v1/entities/pierre-fabre.json